Alpha-1-proteinase inhibitor (Human, Baxalta)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAlpha-1-proteinase inhibitor (Human, Baxalta)
Drug Alias Nameα-1抗胰蛋白酶Alpha-1-antitrypsin (Shire)α-1-蛋白酶抑制剂Aralast
ClassificationBiologics > Blood components
Mechanisms of ActionSerine protease inhibitors
TargetsSerine protease
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Diabetes Mellitus, Type 1Diabetes Mellitus +[5] 
Global Approved Indicationsalpha 1-Antitrypsin Deficiency
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2002/12/23
Country/TerritoryCanadaUnited StatesNew Zealand +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlpha Therapeutic CorpBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShireUniversity Of AlbertaTakeda Pharmaceuticals North America Inc +[7] 
Active Indicationsalpha 1-Antitrypsin Deficiency
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Diabetes Mellitus, Type 1Diabetes Mellitus +[4] 

Other Information

ATC CodeB02AB02
Related LinksWikipedia